drugset / Trial / NCT02665910

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

NCT02665910

Phase 1 Unknown 48 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized

Timeline

Start
2016-05
Primary completion
2016-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown 1 mg Oral
Subject SHR0302 Unknown 2 mg Oral
Subject SHR0302 Unknown 5 mg Oral
Subject SHR0302 Unknown 10 mg Oral
Subject SHR0302 Unknown 25 mg Oral

Indications